Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson’s disease
- 292 Downloads
Tetrahydrobiopterin (BH4) is a cofactor for tyrosine hydroxylase that is essential for the biosynthesis of dopamine. Parkinson’s disease (PD) is characterized by a progressive degeneration of nigrostriatal dopaminergic neurons, and biomarkers reflecting the degree of neurodegeneration are important not only for basic research but also for clinical diagnosis and the treatment of the disease. Although the total neopterin and biopterin levels in the cerebrospinal fluids (CSF) of the patients with PD were reported, alterations in the composition of reduced and oxidized forms of pteridine compounds have not been examined. In this study, we first examined the time-dependent alterations in BH4 and other reduced pteridine compounds in the CSF of an MPTP-treated monkey as a primate PD model. We found that the CSF levels of BH4 and dihydroneopterin, an intermittent metabolite of BH4-biosynthesis, altered inversely with progression of neurodegeneration, whereas those of dihydrobiopterin and neopterin were relatively low and constant. Next, we assayed the amounts of reduced pteridine compounds in the CSF of 36 pre-symptomatic LRRK2-mutation (N1437H or G2019S) carriers (LRRK2-carrier), 13 patients with PD symptoms (LRRK2-PD), 46 patients with sporadic PD (sPD), and 26 non-PD individuals. The BH4 levels were significantly lower in both the LRRK2-PD and sPD patients, and the LRRK2-carriers exhibited higher BH4 levels compared with the sPD patients. The total neopterin levels in the CSF of the LRRK2-PD were significantly higher than those in the sPD and non-PD individuals, which indicated greater inflammatory responses in the brains of LRRK2-PD patients. The present results suggest that detailed analyses of pteridine levels in the CSF might be useful for understanding the pathophysiology of familial PD and for monitoring PD progression.
KeywordsLRRK2 Neopterin PARK8 Parkinson’s disease Tetrahydrobiopterin
This study was supported by a Grant-in-Aid for Scientific Research on Innovative Areas (Adaptive circuit shift) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (15H01422); and by grants from the Health and Labor Sciences Research Grant for Research on Intractable Disease from the Ministry of Health, Labor and Welfare of Japan (H22-nanchi-ippan-123, H23-nanchi-ippan-096).
Compliance with ethical standards
Conflict of interest
The authors declare no competing financial interest.
- Benson M, Batchelor H, Chuaiphichai S, Bailey J, Zhu H, Stuehr D et al (2013) A pivotal role for tryptophan 447 in enzymatic coupling of human endothelial nitric oxide synthase (eNOS). Effects on tetrahydrobiopterin-dependent catalysis and eNOS dimerization. J Biol Chem 288:29836–29845CrossRefPubMedPubMedCentralGoogle Scholar
- Bulteau A-L, Mena N, Auchère F, Lee I, Prigent A, Lobsiger C, Camadro J-M, Hirsch E (2017) Dysfunction of mitochondrial Lon protease and identification of oxidized protein in mouse brain following exposure to MPTP: implications for Parkinson disease. Free Radic Biol Med 108:236–246. doi: 10.1016/j.freeradbiomed.2017.03.036 CrossRefPubMedGoogle Scholar
- Gillardon F, Schmid R, Draheim H (2012) Parkinson’s disease-linked leucine-rich repeat kinase 2 (R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208:41–48. doi: 10.1016/j.neuroscience.2012.02.001 CrossRefPubMedGoogle Scholar
- Noguchi K, Hamadate N, Matsuzaki T, Sakanashi M, Nakasone J, Uchida T, Arakaki K, Kubota H, Ishiuchi S, Masuzaki H, Sugahara K, Ohya Y, Sakanashi M, Tsutsui M (2011) Increasing dihydrobiopterin causes dysfunction of endothelial nitric oxide synthase in rats in vivo. Am J Physiol Hear Circ Physiol 301:H721–H729. doi: 10.1152/ajpheart.01089.2010 CrossRefGoogle Scholar